Form 4: VolitionRx Executive Jasmine Kway Awarded Restricted Stock Units as Compensation

Jasmine Kway, CEO of Singapore Volition, was awarded 8,327 restricted stock units (RSUs) of VolitionRx Ltd. common stock on June 1, 2025, as part of her compensation.

Summary

• Jasmine Kway, the CEO of Singapore Volition, received an award of 8,327 restricted stock units (RSUs) of VolitionRx Ltd. common stock.
• The transaction date for this award was June 1, 2025.
• These RSUs were granted under the Issuer's 2015 Stock Incentive Plan and were provided in lieu of cash compensation.
• The RSUs will vest in three partial installments: 2,776 units on June 1, 2025, 2,776 units on July 1, 2025, and 2,775 units on August 1, 2025.
• Vesting is also subject to further time-based vesting in a single installment on August 1, 2025, and generally requires continued service through each applicable vesting date.
• Upon vesting and settlement, Ms. Kway will receive shares of common stock equal to the number of vested RSUs.
• Following this transaction, Ms. Kway directly beneficially owns 191,107 shares of common stock and indirectly owns 10,400 shares through her spouse.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates alignment of executive interests with shareholders through equity compensation, which is a standard and generally favorable practice. It is not a major market-moving event.

Positives

• The award of restricted stock units to a key executive like Jasmine Kway aligns management's interests with those of shareholders, as her compensation is tied to the company's stock performance.
• Utilizing equity compensation in lieu of cash can help conserve the company's cash reserves, which can be beneficial for operational liquidity or other strategic investments.

Risks

• The restricted stock units are subject to vesting conditions, including continued service, meaning Ms. Kway must remain employed by the company until the vesting dates to receive the shares.
• The value of the compensation is tied to the future stock price of VolitionRx Ltd., meaning the actual value realized by Ms. Kway could be lower than the initial grant value if the stock price declines.

Future Outlook

This Form 4 filing pertains to an executive compensation award and does not contain forward-looking statements or guidance regarding the company's financial performance or strategic outlook.

Management Comments

• Jasmine Kway, CEO of Singapore Volition, was awarded 8,327 restricted stock units under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation.

Industry Context

The practice of awarding restricted stock units (RSUs) to executives is a common form of equity compensation across various industries, particularly in technology and biotechnology sectors like VolitionRx. It serves to attract, retain, and incentivize key personnel by aligning their financial interests with the long-term performance of the company's stock.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a component of executive compensation is a widely adopted practice across publicly traded companies, including those in the biotechnology and diagnostics sectors, such as Exact Sciences Corp. (EXAS) or Guardant Health, Inc. (GH).
• Equity awards like RSUs are typically structured with vesting schedules (e.g., multi-year or performance-based) to encourage long-term commitment and performance, similar to how executives at companies like Illumina, Inc. (ILMN) or Bio-Rad Laboratories, Inc. (BIO) might receive their equity incentives.
• The grant of RSUs in lieu of cash compensation is also a common strategy, especially for companies looking to manage cash flow while still providing competitive executive remuneration, a practice observed in various growth-oriented companies.

Stakeholder Impact

• Shareholders: The award of RSUs to an executive can align management's incentives with shareholder value creation, as the executive's compensation is tied to the company's stock performance.
• Employees: This type of compensation structure can set a precedent for how key personnel are incentivized, potentially influencing broader compensation strategies within the company.

Next Steps

• The restricted stock units are scheduled to vest in three installments on June 1, 2025, July 1, 2025, and August 1, 2025, subject to continued service.

Key Dates

Keywords

VolitionRx, VNRX, Restricted Stock Units, RSUs, Executive Compensation, Insider Transaction, SEC Form 4, Equity Award, Stock Incentive Plan